New combo therapy for endometrial cancer shows promise in early trial

This early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard radiation and chemotherapy is safe and feasible for people with high-intermediate risk endometrial cancer. About 45 participants who have already had surgery to remove the uterus will receive radiation to the vagina, followed by three cycles of pembrolizumab plus chemotherapy. The main goal is to see how many people can complete all three cycles of the combined treatment.